Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

Maintain ADD on Torrent Pharma - Steady show - HDFC Securities

Posted On: 2020-10-26 23:04:49


Ms. Bansi Desai, Institutional Research Analyst, HDFC Securities

Torrent's Q2 performance reflects resilience in India business (+7% YoY) EBITDA margin was strong at 31.5% (+450bps YoY, down 67bps QoQ) driven by cost savings. Barring US, most businesses witnessed improved traction. The company repaid debt of Rs4.4bn in 1H and is on track to reduce it by Rs10bn in FY21. We like Torrent's India franchise and its superior return profile. Higher contribution from India justifies the premium multiple over peers. We tweak our estimates by 6%/-3%/1% in FY21/22/23 and revise our TP to Rs2,675 (from Rs2745) based on 16x EV/EBIDTA. Maintain ADD.

Margin beat continues, to moderate in the future: Revenues grew by 1% to Rs20bn as good growth in India (+7% YoY), Germany (+4% YoY) was offset by Brazil (down 18% YoY, +5% in cc terms, currency depreciation) and US (down 9% QoQ, lack of new launches). Gross margin was impacted in Q2FY21 (72.5%, down 150bps QoQ) due to higher inventory provision. However, EBITDA margin was strong at 31.5% (+450bps YoY, -67bps QoQ) driven by lower other expenses (down 128bps QoQ, several one offs in Q1).

India continues to outperform: Revenues grew by 7% YoY vs. IPM growth of 1% for Q2FY21. Key brands such as Shelcal, Losar continue to do well. New launches in cardio, diabetes and gastro will contribute to sales growth. Field force activity was at 75-80% of pre-covid levels in Q2 with Sep month at ~90%+ levels. We expect India business to outperform the industry growth driven by chronic and semi-chronic portfolio (~77% of 1H sales). Price led growth is likely to continue for few years.

US business witnessed pressure: US business (USD43mn, down 9% QoQ, down 18% YoY) was impacted by price erosion, lack of new launches and discontinuation of sartans (plans to re enter after resolving issues). We expect gradual recovery in US driven by re launches from Levittown facility beginning from Mar 21 and new approvals (third party sourced).

Key call takeaways: a) India - Promotional spends to inch up as field force activity increases from ~75-80% in Q2 to 90%+ in Q3; b) Germany - issues are largely resolved, market share is back to 6% levels; c) Net debt at Rs42bn, Net Debt/EBITDA - 1.7x, repaid Rs4.4bn in 1H and on track to trim further in 2H; d) Dahej and Indrad - submitted CAPA, awaiting re-inspection; e) Brazil - phased discontinuation of tender business.

Shares of TORRENT PHARMACEUTICALS LTD. was last trading in BSE at Rs.2654.45 as compared to the previous close of Rs. 2734.35. The total number of shares traded during the day was 23676 in over 2381 trades.

The stock hit an intraday high of Rs. 2773.85 and intraday low of 2644. The net turnover during the day was Rs. 63804283.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com



Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Astral Poly Technik - Scalability to further improve with storage tanks foray - ICICI Securities

Vardhman Special Steel - Q2FY21 Company Update - ICICI Direct

Initiating Coverage - Advanced Enzyme Technologies - ICICI Direct

L&T - Secures Large Contract - Nov 25, 2020 - Angel Broking

Alembic Pharmaceuticals - Tentative Approval for JV - Angel Broking

Drug launch by Lupin - Tacrolimus Capsules - Angel Broking

Gujarat Gas - Nov 25, 2020 - Angel Broking

Metropolis Healthcare - Nov 25, 2020 - Angel Broking

NTPC - Showcase of strength & competitiveness - ICICI Securities

Telecom - Market Share TRACKER - Bharti is narrowing the gap on incremental market share vs RJio - ICICI Securities

Cochin Shipyard - Q2FY21 Result Update - ICICI Direct

Engineers India - Q2FY21 Result Update - ICICI Direct

Rupee - Nov 24, 2020 - Reliance Securities

FMCG Sector Update - Recovery unlocked; lower growth divergence - HDFC Securities

Engineers India - Consultancy segment outperformance - ICICI Securities

Engineers India - Q2 FY21 Result Update - YES SECURITIES

Motherson Sumi Systems - Company Update - Virtual Investor Conference - ICICI Direct

Mutual Fund Review - November, 2020 - ICICI Direct

Sadbhav Engineering - Q2FY21 Company Update - ICICI Direct

IRB Infrastructure - Q2FY21 Company Update - ICICI Direct

Vodafone Idea fund raising - Angel Broking

Rupee - Nov 23, 2020 - Reliance Securities

Crude Oil - Nov 23, 2020 - Reliance Securities

Q2FY21 Bank Result Quick Review - Angel Broking

Banks & NBFC's Sector Update Report - Yet another watershed moment? - HDFC Securities

Galaxy Surfactants - EBITDA/kg has an upside risk - ICICI Securities

Diagnostics - COVID-19 tests continue to trend higher - ICICI Securities

Banking & Financial Services - Sector Update - Nov 22, 2020 - ICICI Direct

Dalmia Bharat Sugar - Q2FY21 Company Update - ICICI Direct

Balkrishna Industries - Industry export growth momentum continues - ICICI Securities

Covid Recovery Pulse - Festive positivity continues in auto retails, E-way bill generation improves... - ICICI Direct

Quant Pick - Exide Industries - ICICI Direct

Shankara Building Products - Q2FY21 Company Update - ICICI Direct

Triveni Engineering - Q2FY21 Company Update - ICICI Direct

Initiating Coverage on Sudarshan Chemical - Leaping into the league of giants - HDFC Securities

Earnings Wrap Q2FY21: Earnings outperform, post Covid recovery picks up steam - ICICI Direct

Vodafone Idea Positive development beneficial for IDFC first bank - Angel Broking

Lakshmi Vilas Bank - Angel Broking

WIPRO Buyback record date announcement - Angel Broking

TCS buyback record date announcement - Angel Broking

Banks Sector Update - Collection efficiency - a positive surprise! - HDFC Securities

Quant Pick - Max Financial Services - ICICI Direct

Graphite India - Q2FY21 Result Update - ICICI Direct

Gladiator Stocks - Maruti Suzuki India - ICICI Direct

Exide Industries - Q2FY21 Result Update - ICICI Direct

Mishra Dhatu Nigam - Execution outlook remains strong - ICICI Securities

Bharat Electronics - Diversifying into multiple revenue streams - ICICI Securities

Wipro Ltd - Virtual Analyst Meet Update - ICICI Direct

Avadh Sugar & Energy - November 2020 - Company Update - ICICI Direct

Mahindra Lifespace Developers - H1FY21 Company Update - ICICI Direct



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019